Tumor mutational burden as a predictor of immunotherapy response in breast cancer.
breast cancer
immunotherapy
tumor mutational burden
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
02 Mar 2021
02 Mar 2021
Historique:
received:
09
01
2021
accepted:
19
01
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
Tumor mutational burden (TMB) is a promising tool to help define patients with triple-negative breast cancer (TNBC) most likely to benefit from immune checkpoint blockade (ICB) therapies. Roughly reflecting the degree of neo-antigens that tumors present to immune cells, TMB associates with multiple measures of tumoral immunogenicity and has proven clinically useful in cancers with relatively high mutation burden. TNBC carries higher TMB than other breast cancer subtypes, and recent data suggest that high-TMB TNBC cases may derive particular benefit from ICB in combination with chemotherapy (GeparNuevo, IMpassion130) or even ICB alone (KEYNOTE-119, TAPUR). Given the recent approval of pembrolizumab and atezolizumab in combination with chemotherapy for PD-L1-positive, metastatic TNBC, standardizing TMB calculation methods and cut-off values is of critical importance to deploy this clinical biomarker.
Identifiants
pubmed: 33747355
doi: 10.18632/oncotarget.27877
pii: 27877
pmc: PMC7939529
doi:
Types de publication
Journal Article
Langues
eng
Pagination
394-400Informations de copyright
Copyright: © 2021 O’Meara and Tolaney.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST SMT reports institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, Seattle Genetics; and advisor/consultant role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Gilead, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Odonate, Seattle Genetics, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Samsung Bioepsis Inc.
Références
Cancer Immunol Immunother. 2020 Oct;69(10):1943-1945
pubmed: 32725361
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Cell Rep Med. 2020 Jun 23;1(3):
pubmed: 32676589
Cancer Discov. 2017 Jul;7(7):675-693
pubmed: 28630051
J Natl Compr Canc Netw. 2020 May;18(5):517-521
pubmed: 32380464
Ann Oncol. 2020 Sep;31(9):1216-1222
pubmed: 32461104
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
JAMA Oncol. 2019 Apr 11;:
pubmed: 30973611
Hum Pathol. 2018 Feb;72:28-34
pubmed: 28843709
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
PLoS One. 2017 Nov 21;12(11):e0188174
pubmed: 29161279
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Ann Oncol. 2019 Jul 1;30(7):1096-1103
pubmed: 31038663
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
JAMA Oncol. 2016 Oct 1;2(10):1354-1360
pubmed: 27355489
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
Breast Cancer Res. 2019 Jul 5;21(1):78
pubmed: 31277699
Breast Cancer Res Treat. 2014 Jul;146(1):211-20
pubmed: 24839032
Cancer Res. 2017 Jun 15;77(12):3317-3324
pubmed: 28428277
Lancet. 2020 Oct 10;396(10257):1046-1048
pubmed: 32966831
Histopathology. 2020 Jan;76(2):191-200
pubmed: 31243779
BMC Med. 2019 May 9;17(1):90
pubmed: 31068190
Diagn Pathol. 2020 May 11;15(1):50
pubmed: 32393302
Nat Rev Cancer. 2020 Jan;20(1):12-25
pubmed: 31806885
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
J Hematol Oncol. 2019 May 31;12(1):54
pubmed: 31151482
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Int J Cancer. 2019 Feb 15;144(4):848-858
pubmed: 30238975
J Immunother Cancer. 2019 Jul 15;7(1):183
pubmed: 31307554
Nat Genet. 2019 Oct;51(10):1450-1458
pubmed: 31570896
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Clin Cancer Res. 2020 Jun 1;26(11):2565-2572
pubmed: 32019858
Clin Cancer Res. 2021 Feb 15;27(4):1105-1118
pubmed: 33293374
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
JAMA Oncol. 2017 Dec 1;3(12):1707-1711
pubmed: 28750120
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Am J Surg Pathol. 2018 Feb;42(2):183-191
pubmed: 28914717
J Clin Invest. 2018 Oct 1;128(10):4236-4242
pubmed: 30272580